Chromosome 12p Amplification in Triple-Negative/ <i>BRCA1-</i> Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity
Jorge Gómez‐Miragaya(Institut d'Investigació Biomédica de Bellvitge), Eva González‐Suárez(Institut d'Investigació Biomédica de Bellvitge), Eva M. Trinidad(Institut d'Investigació Biomédica de Bellvitge), Miguel Ángel Pujana(Bellvitge University Hospital), Suhas Vasaikar(Baylor College of Medicine), Gerburg M. Wulf(Beth Israel Deaconess Medical Center), Ander Díaz‐Navarro(Universidad de Oviedo), Marta Palafox(Vall d'Hebron Institute of Oncology), María Teresa Soler-Monsó(Institut d'Investigació Biomédica de Bellvitge), Raúl Tonda(Universitat Pompeu Fabra), Michael T. Lewis(Baylor College of Medicine), Alejandro Collado-Solé(Spanish National Cancer Research Centre), Chen Huang(Baylor College of Medicine), Lacey E. Dobrolecki(Baylor College of Medicine), Luís Palomero(Institut d'Investigació Biomédica de Bellvitge), Sergi Beltrán(Centro Nacional de Análisis Genómico), Laia Paré(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Alejandra Bruna(Institute of Cancer Research), Violeta Serra(Vall d'Hebron Institute of Oncology), Joaquı́n Arribas(Hospital Del Mar), Judith Balmañà(Vall d'Hebron Hospital Universitari), Carlos Caldas(University of Cambridge), Aleix Prat(Hospital Clínic de Barcelona), Xosé S. Puente(Universidad de Oviedo), Bing Zhang(Baylor Genetics), Cristina Cruz(Vall d'Hebron Institut de Recerca), Anna Petit(Bellvitge University Hospital), Purificacı́on Muñoz(Institut d'Investigació Biomédica de Bellvitge)
Cited by 19
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
|Nature|2014|2.4k
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
|Breast Cancer Research|2010|2.1k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k